Objective: To investigate the therapeutic effects of strontium-89 against osseous metastases of lung cancer.
Methods: A total of 126 patients with osseous metastases of lung cancer received strontium-89 treatment ((89)SrCl(2)) at the dose of 148 MBq given through a single intravenous injection. The analgesic effect was evaluated by the changes in the degree, frequency and scores of the pain, and the therapeutic effect assessed by observing the changes in the number and volume of osseous lesions after therapy and compared between different pathological types of lung cancer by Ka-square test.
Results: Within 6 months after the injection, the total pain relief rate was 70.6% (89/126), including 25 (19.8%) cases with pain vanished, suggesting significant alleviation of the pain intensity by the treatment (u=5.361, P<0.01). The frequency of pain was reduced in 78.6% (99/126) of the cases (u=4.589, P<0.01), and the average score of pain decreased significantly from 7.54+/-3.29 to 4.19+/-4.38 (t=6.865, P<0.001). The number and size of lesions decreased by more than 25% in 57 cases, showing a total efficacy rate of 45.2% (57/126). No significant difference was noted in the therapeutic effects among the 4 pathological types of lung cancer (P>0.05).
Conclusions: Strontium-89 is effective for pain relief and tumor focus confinement in osseous metastases of lung cancer. No significant difference has been found in its effect between 4 different pathological types of lung cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [Ga]Ga/[Lu]Lu-NYM032 for theranostic use in prostate cancer.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu Province, 214000, China.
Article Synopsis
- A new theranostic radiopharmaceutical, [Ga]Ga/[Lu]Lu-NYM032, was developed to target prostate-specific membrane antigen (PSMA) for diagnosing and treating prostate cancer (PCa).
- In preclinical studies, [Ga]Ga-NYM032 showed high specificity and uptake in PSMA-positive tumors, outperforming a comparator in detecting bone and lymph node metastases.
- The therapeutic component, [Lu]Lu-NYM032, demonstrated effectiveness in inhibiting tumor growth in animal models, with larger doses leading to significantly smaller tumor sizes.
Surgical management of cervical malignant spinal lesions: a retrospective study of cervical spine metastases and multiple myeloma cases.
Acta Neurochir (Wien)
December 2024
Department of Spine Surgery, Zentralklinik Bad Berka, Bad Berka, Germany.
Purpose: This study introduces a retrospective analysis of the surgical management of 213 consecutive cases of cervical spine metastases and Multiple Myeloma Cases.
Materials And Methods: Retrospective analysis of prospectively collected data in a single surgical center of patients who underwent surgery for tumors of the cervical spine between 1994 and 2017. Exclusion criteria were intradural tumors and primary tumors.
Combined interdisciplinary treatment of metastatic bone lesions using 3D robot-assisted image-guided navigation : Embolization, biopsy, ablation, and surgery in one operative session.
Oper Orthop Traumatol
December 2024
Department for Orthopaedic and Trauma Surgery, Lucerne Cantonal Hospital LUKS, Spitalstrasse, Lucerne, Switzerland.
Objective: To maximize local tumor control, stabilize affected bones, and preserve or replace joints with minimal interventional burden, thereby enhancing quality of life for empowered living.
Indications: Suitable for patients with bone metastases, particularly those with severe pain and/or fractures and appropriate life expectancy.
Contraindications: In primary bone tumors, refer to the sarcoma surgery team for evaluation of wide resection.
High Fracture Risk of Femoral Bone Metastasis Treated with Palliative Radiotherapy in Recent Years.
Curr Oncol
November 2024
Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Chiba, Japan.
Bone-modifying agents (BMAs) have been widely used to reduce skeletal-related events, including pathological fractures. Herein, we aimed to clarify the incidence of pathological fractures caused by high-risk femoral bone metastases after palliative radiotherapy (RT) in the BMA era and evaluate the necessity of prophylactic surgical stabilization. We assessed 90 patients with high-risk femoral bone metastases, indicated by Mirels' scores ≥ 8, without pathological fractures and surgical fixations, who received palliative RT at our institution between January 2009 and December 2018.
View Article and Find Full Text PDFEGFR, TP53, and CUL3 Triple Mutation in Non-Small Cell Lung Cancer and its Potentially Poor Prognosis: A Case Report and Database Analysis.
Thorac Cancer
December 2024
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Concurrent mutations in tumor protein p53 (TP53) or Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-pathway components are linked to poor outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), but the impact of triple mutations remains unclear. We report a case of EGFR-, TP53-, and Cullin 3 (CUL3)-mutant NSCLC in a 43-year-old woman with widespread metastases at diagnosis, including those in the contralateral lung, distant lymph nodes, pericardium, liver, bones, left adrenal gland, and brain. She received osimertinib as first-line therapy, but pericardial effusion and liver metastases progressed rapidly over 3 months, and she was switched to carboplatin and pemetrexed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!